{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:16:24Z","timestamp":1791612984112,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s15010-026-02815-w","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:24:06Z","timestamp":1779103446000},"page":"1787-1801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions"],"prefix":"10.1007","volume":"54","author":[{"given":"Durga Shankar","family":"Meena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal Krishana","family":"Bohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"9","key":"2815_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.recesp.2013.05.003","volume":"66","author":"N Fern\u00e1ndez-Hidalgo","year":"2013","unstructured":"Fern\u00e1ndez-Hidalgo N, Tornos Mas P. Epidemiology of infective endocarditis in Spain in the last 20 years. Rev Esp Cardiol (Engl Ed). 2013;66(9):728\u201333.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"43","key":"2815_CR2","doi-asserted-by":"publisher","first-page":"e1816","DOI":"10.1097\/MD.0000000000001816","volume":"94","author":"P Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz P, Kestler M, De Alarcon A, et al. Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en Espa\u00f1a (GAMES) (see Acknowledgment). Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study. Med (Baltim). 2015;94(43):e1816.","journal-title":"Med (Baltim)"},{"issue":"25","key":"2815_CR3","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.119.044913","volume":"141","author":"ASV Shah","year":"2020","unstructured":"Shah ASV, McAllister DA, Gallacher P, et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis. Circulation. 2020;141(25):2067\u201377.","journal-title":"Circulation"},{"issue":"4","key":"2815_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/431979","volume":"41","author":"JM Miro","year":"2005","unstructured":"Miro JM, Anguera I, Cabell CH, Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the international collaboration on endocarditis merged database. Clin Infect Dis. 2005;41(4):507\u201314.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"2815_CR5","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","volume":"293","author":"VG Fowler Jr","year":"2005","unstructured":"Fowler VG Jr, Miro JM, Hoen B, et al. ICE investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012\u201321.","journal-title":"JAMA"},{"issue":"5","key":"2815_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/archinte.159.5.462","volume":"159","author":"BL R\u00f8der","year":"1999","unstructured":"R\u00f8der BL, Wandall DA, Frimodt-M\u00f8ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med. 1999;159(5):462\u20139.","journal-title":"Arch Intern Med"},{"issue":"3","key":"2815_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1128\/AAC.02192-12","volume":"57","author":"PA Moise","year":"2013","unstructured":"Moise PA, Amodio-Groton M, Rashid M, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant \u03b2-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013;57(3):1192\u2013200.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2815_CR8","doi-asserted-by":"publisher","first-page":"107015","DOI":"10.1016\/j.ijantimicag.2023.107015","volume":"63","author":"E Yusuf","year":"2024","unstructured":"Yusuf E, Bramer W, Anas AA. Clinical outcomes of rifampicin combination therapy in implant-associated infections due to staphylococci and streptococci: a systematic review and meta-analysis. Int J Antimicrob Agents. 2024;63(1):107015.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2815_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciz746","volume":"71","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin plus \u03b2-Lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis. 2020;71(1):1\u201310.","journal-title":"Clin Infect Dis"},{"key":"2815_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","volume":"17","author":"SY Tong","year":"2016","unstructured":"Tong SY, Nelson J, Paterson DL, CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network, et al. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. 2016;17:170.","journal-title":"Trials"},{"issue":"11","key":"2815_CR11","doi-asserted-by":"publisher","first-page":"ofac583","DOI":"10.1093\/ofid\/ofac583","volume":"9","author":"JH Ryder","year":"2022","unstructured":"Ryder JH, Tong SYC, Gallagher JC, et al. Systematic literature review and meta-analysis of adjunctive gentamicin and Rifampin in Staphylococcal Prosthetic Valve endocarditis. Open Forum Infect Dis. 2022;9(11):ofac583.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2815_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s15010-024-02421-8","volume":"53","author":"H Suzuki","year":"2025","unstructured":"Suzuki H, Pandya A, Hasegawa S, et al. Association between adjunctive rifampin and gentamicin use and outcomes for patients with staphylococcal prosthetic valve endocarditis: a propensity-score adjusted retrospective cohort study. Infection. 2025;53(2):607\u201314.","journal-title":"Infection"},{"issue":"3","key":"2815_CR13","doi-asserted-by":"publisher","first-page":"106735","DOI":"10.1016\/j.ijantimicag.2023.106735","volume":"61","author":"D Patel","year":"2023","unstructured":"Patel D, Brown ML, Edwards S, et al. Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia. Int J Antimicrob Agents. 2023;61(3):106735.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2815_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2815_CR15","doi-asserted-by":"publisher","first-page":"e2451353","DOI":"10.1001\/jamanetworkopen.2024.51353","volume":"7","author":"B Jean","year":"2024","unstructured":"Jean B, Crolle M, Pollani C, et al. \u03b2-Lactam inoculum effect in Methicillin-susceptible Staphylococcus aureus infective endocarditis. JAMA Netw Open. 2024;7(12):e2451353.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2815_CR16","doi-asserted-by":"publisher","first-page":"e2451300","DOI":"10.1001\/jamanetworkopen.2024.51300","volume":"7","author":"SE Cosgrove","year":"2024","unstructured":"Cosgrove SE, Miller LG. The inoculum effect and Staphylococcus aureus infective endocarditis-time to reconsider treatment? JAMA Netw Open. 2024;7(12):e2451300.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2815_CR17","doi-asserted-by":"publisher","first-page":"e00157","DOI":"10.1128\/AAC.00157-18","volume":"62","author":"N Tran","year":"2018","unstructured":"Tran N, Rybak MJ. \u03b2-Lactam combinations with vancomycin show synergistic activity against vancomycin-susceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and Heterogeneous VISA. Antimicrob Agents Chemother. 2018;62(6):e00157\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2815_CR18","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1128\/AAC.00636-09","volume":"53","author":"C Vidaillac","year":"2009","unstructured":"Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother. 2009;53(11):4712\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"2815_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijid.2022.05.057","volume":"122","author":"CE Tsai","year":"2022","unstructured":"Tsai CE, Yang CJ, Chuang YC, et al. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus. Int J Infect Dis. 2022;122:230\u20136.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"2815_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/antibiotics13121132","volume":"13","author":"A Kaushik","year":"2024","unstructured":"Kaushik A, Kest H, Sood M, et al. Infective Endocarditis by Biofilm-Producing Methicillin-Resistant Staphylococcus aureus-Pathogenesis, Diagnosis, and Management. Antibiot (Basel). 2024;13(12):1132.","journal-title":"Antibiot (Basel)"},{"key":"2815_CR21","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Hidalgo N, Basas J, Viedma E et al. Association between biomass formation and the prognosis of infective endocarditis due to Staphylococcus aureus. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jun-Jul;38(6):263\u20136. English, Spanish.","DOI":"10.1016\/j.eimce.2019.10.008"},{"issue":"10121","key":"2815_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","volume":"391","author":"GE Thwaites","year":"2018","unstructured":"Thwaites GE, Scarborough M, Szubert A, United Kingdom Clinical Infection Research Group (UKCIRG), et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668\u201378.","journal-title":"Lancet"},{"issue":"9","key":"2815_CR23","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1093\/cid\/ciaa1040","volume":"72","author":"A Le Bot","year":"2021","unstructured":"Le Bot A, Lecomte R, Gazeau P, et al. Is Rifampin use associated with better outcome in Staphylococcal prosthetic valve endocarditis? A multicenter retrospective study. Clin Infect Dis. 2021;72(9):e249\u201355.","journal-title":"Clin Infect Dis"},{"key":"2815_CR24","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler","year":"2006","unstructured":"Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653\u201365.","journal-title":"N Engl J Med"},{"key":"2815_CR25","doi-asserted-by":"crossref","unstructured":"Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother; 2019.","DOI":"10.1128\/AAC.02483-18"},{"key":"2815_CR26","doi-asserted-by":"crossref","unstructured":"Ahmad O, Crawford TN, Myint T. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus monotherapy in adults with complicated and prolonged methicillin-resistant Staphylococcus aureus bacteremia initially treated with supplemental ceftaroline. Infect Dis Ther 2020.","DOI":"10.1007\/s40121-019-00277-2"},{"issue":"9","key":"2815_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/cid\/ciz018","volume":"69","author":"S Grillo","year":"2019","unstructured":"Grillo S, Cuervo G, Carratal\u00e0 J, et al. Impact of \u03b2-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019;69(9):1480\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2815_CR28","doi-asserted-by":"publisher","first-page":"e0164921","DOI":"10.1128\/AAC.01649-21","volume":"66","author":"NN Mishra","year":"2022","unstructured":"Mishra NN, Lew C, Abdelhady W, et al. Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics. Antimicrob Agents Chemother. 2022;66(1):e0164921.","journal-title":"Antimicrob Agents Chemother"},{"key":"2815_CR29","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1128\/AAC.01192-16","volume":"60","author":"G Sakoulas","year":"2016","unstructured":"Sakoulas G, Olson J, Yim J, et al. Cefazolin and Ertapenem, a synergistic combination used to clear persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016;60:6609\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"2815_CR30","doi-asserted-by":"publisher","first-page":"ofac159","DOI":"10.1093\/ofid\/ofac159","volume":"9","author":"J Gilbertie","year":"2022","unstructured":"Gilbertie J, Ulloa ER, Daiker JC, et al. Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-Susceptible Staphylococcus aureus Endocarditis. Open Forum Infect Dis. 2022;9:ofac159.","journal-title":"Open Forum Infect Dis"},{"issue":"39","key":"2815_CR31","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"V Delgado","year":"2023","unstructured":"Delgado V, Ajmone Marsan N, de Waha S, ESC Scientific Document Group, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948\u20134042.","journal-title":"Eur Heart J"},{"key":"2815_CR32","doi-asserted-by":"publisher","unstructured":"Baddour LM, Wilson WR, Bayer AS, American Heart Association Committee on Rheumatic Fever., Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435-86. https:\/\/doi.org\/10.1161\/CIR.0000000000000296. Epub 2015 Sep 15. Erratum in: Circulation. 2015;132(17):e215.","DOI":"10.1161\/CIR.0000000000000296"},{"issue":"7","key":"2815_CR33","doi-asserted-by":"publisher","first-page":"e2326366","DOI":"10.1001\/jamanetworkopen.2023.26366","volume":"6","author":"EG McDonald","year":"2023","unstructured":"McDonald EG, Aggrey G, Aslan AT, et al. Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement. JAMA Netw Open. 2023;6(7):e2326366.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2815_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.7326\/0003-4819-97-4-496","volume":"97","author":"O Korzeniowski","year":"1982","unstructured":"Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982;97(4):496\u2013503.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2815_CR35","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1128\/AAC.00300-08","volume":"52","author":"DJ Riedel","year":"2008","unstructured":"Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(7):2463\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2815_CR36","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41591-023-02569-0","volume":"29","author":"S Grillo","year":"2023","unstructured":"Grillo S, Pujol M, Mir\u00f3 JM, et al. SAFO study group. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023;29(10):2518\u201325.","journal-title":"Nat Med"},{"issue":"6","key":"2815_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/cid\/ciz995","volume":"71","author":"ER Ulloa","year":"2020","unstructured":"Ulloa ER, Singh KV, Geriak M, et al. Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible Staphylococcus aureus Bacteremia. Clin Infect Dis. 2020;71(6):1413\u20138.","journal-title":"Clin Infect Dis"},{"key":"2815_CR38","doi-asserted-by":"publisher","first-page":"dlab148","DOI":"10.1093\/jacamr\/dlab148","volume":"3","author":"S El-Dalati","year":"2021","unstructured":"El-Dalati S, Sridaran S, Uricchio M, Kline EG, Shields R. Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series. JAC Antimicrob Resist. 2021;3:dlab148.","journal-title":"JAC Antimicrob Resist"},{"key":"2815_CR39","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/jac\/dkae198","volume":"79","author":"S Shah","year":"2024","unstructured":"Shah S, Clarke LG, Ludwig J, Burgdorf S, Arbulu Guerra RD, Shields RK. Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2024;79:1990\u201397.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2815_CR40","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","volume":"72","author":"M Pujol","year":"2021","unstructured":"Pujol M, Mir\u00f3 JM, Shaw E, et al. MRSA Bacteremia (BACSARM) trial investigators. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus Bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis. 2021;72(9):1517\u201325.","journal-title":"Clin Infect Dis"},{"key":"2815_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/597031","volume":"48","author":"SE Cosgrove","year":"2009","unstructured":"Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48:713\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2815_CR42","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s15010-011-0189-2","volume":"39","author":"TL Lemonovich","year":"2011","unstructured":"Lemonovich TL, Haynes K, Lautenbach E, et al. Combination therapy with an aminoglycoside for Staphylococcus aureus endocarditis and\/or persistent bacteremia is associated with a decreased rate of recurrent bacteremia: a cohort study. Infection. 2011;39(6):549\u201354.","journal-title":"Infection"},{"issue":"5","key":"2815_CR43","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/jac\/dkg440","volume":"52","author":"D Drinkovi\u0107","year":"2003","unstructured":"Drinkovi\u0107 D, Morris AJ, Pottumarthy S, et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother. 2003;52(5):820\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2815_CR44","doi-asserted-by":"publisher","first-page":"e01377","DOI":"10.1128\/AAC.01377-20","volume":"64","author":"C Wang","year":"2020","unstructured":"Wang C, Ye C, Liao L, et al. Adjuvant \u03b2-Lactam therapy combined with vancomycin or daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2020;64(11):e01377\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2815_CR45","doi-asserted-by":"publisher","first-page":"dlaf101","DOI":"10.1093\/jacamr\/dlaf101","volume":"7","author":"A Mourad","year":"2025","unstructured":"Mourad A, Parsons JB, Skalla LA, et al. Combination therapy with fosfomycin for Staphylococcus aureus bacteraemia or endocarditis: a systematic review and meta-analysis of randomized trials. JAC Antimicrob Resist. 2025;7(3):dlaf101.","journal-title":"JAC Antimicrob Resist"},{"issue":"6","key":"2815_CR46","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.athoracsur.2015.11.015","volume":"101","author":"NK Shrestha","year":"2016","unstructured":"Shrestha NK, Shah SY, Wang H, et al. Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study. Ann Thorac Surg. 2016;101(6):2243\u201350.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"2815_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jiac.2018.03.003","volume":"24","author":"A Ramos-Mart\u00ednez","year":"2018","unstructured":"Ramos-Mart\u00ednez A, Mu\u00f1oz Serrano A, de Alarc\u00f3n Gonz\u00e1lez A, et al. Spanish collaboration on endocarditis grupo de Apoyo al Manejo de la endocarditis infecciosa en Espa\u00f1a (GAMES). Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis. J Infect Chemother. 2018;24(7):555\u201362.","journal-title":"J Infect Chemother"},{"issue":"1","key":"2815_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1128\/AAC.01586-12","volume":"57","author":"BJ Werth","year":"2013","unstructured":"Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(1):66\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2815_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1574884715666210108103813","volume":"16","author":"J Eliazar","year":"2021","unstructured":"Eliazar J, Johnson T, Chbib C. Pre-clinical impact of the synergistic mechanism of daptomycin and ceftaroline on patients with Methicillin-resistant Staphylococcus aureus Bacteremia infections. Curr Rev Clin Exp Pharmacol. 2021;16(4):296\u20139.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"2815_CR50","first-page":"204993611988650","volume":"6","author":"JP Hornak","year":"2019","unstructured":"Hornak JP, Anjum S, Reynoso D. Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure. Ther Adv Infect Dis. 2019;6:2049936119886504.","journal-title":"Ther Adv Infect Dis"},{"issue":"3","key":"2815_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/infdis\/jiaf245","volume":"232","author":"C Garc\u00eda-de-la-M\u00e0ria","year":"2025","unstructured":"Garc\u00eda-de-la-M\u00e0ria C, Gasch O, Ca\u00f1as-Pacheco MA, et al. Time to reappraise the antibiotic treatment for Methicillin-susceptible Staphylococcus aureus infective endocarditis: data from the experimental model. J Infect Dis. 2025;232(3):540\u20139.","journal-title":"J Infect Dis"},{"issue":"12","key":"2815_CR52","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s40121-024-01068-0","volume":"13","author":"KE Caniff","year":"2024","unstructured":"Caniff KE, Judd C, Lucas K, et al. Heartfelt impact: a descriptive analysis of ceftaroline-containing regimens in endocarditis due to Methicillin-resistant Staphylococcus aureus. Infect Dis Ther. 2024;13(12):2649\u201362.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"2815_CR53","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1128\/AAC.47.9.3002-3004.2003","volume":"47","author":"FY Chiang","year":"2003","unstructured":"Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(9):3002\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2815_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijantimicag.2004.03.013","volume":"24","author":"C Jacqueline","year":"2004","unstructured":"Jacqueline C, Asseray N, Batard E, et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24(4):393\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"2815_CR55","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/jac\/dkad316","volume":"78","author":"M Bock","year":"2023","unstructured":"Bock M, Van Hasselt JGC, Schwartz F, et al. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis. J Antimicrob Chemother. 2023;78(12):2840\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2815_CR56","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jiac.2018.02.006","volume":"24","author":"M Yazaki","year":"2018","unstructured":"Yazaki M, Oami T, Nakanishi K, et al. A successful salvage therapy with daptomycin and linezolid for right-sided infective endocarditis and septic pulmonary embolism caused by methicillin-resistant Staphylococcus aureus. J Infect Chemother. 2018;24(10):845\u20138.","journal-title":"J Infect Chemother"},{"issue":"14","key":"2815_CR57","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ajhp\/zxz101","volume":"76","author":"KM Galanter","year":"2019","unstructured":"Galanter KM, Ho J. Treatment of tricuspid valve endocarditis with daptomycin and linezolid therapy. Am J Health Syst Pharm. 2019;76(14):1033\u20136.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"2815_CR58","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/jac\/dkaf149","volume":"80","author":"MA Ca\u00f1as","year":"2025","unstructured":"Ca\u00f1as MA, Garc\u00eda-de-la-M\u00e0ria C, Garc\u00eda-Gonz\u00e1lez J, HOSPITAL CLINIC ENDOCARDITIS STUDY GROUP, et al. Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains. J Antimicrob Chemother. 2025;80(7):1933\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2815_CR59","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","volume":"54","author":"H Tissot-Dupont","year":"2019","unstructured":"Tissot-Dupont H, Gouriet F, Oliver L, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 2019;54(2):143\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2815_CR60","first-page":"45","volume":"21","author":"P Di Carlo","year":"2013","unstructured":"Di Carlo P, D\u2019Alessandro N, Guadagnino G, et al. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med. 2013;21(1):45\u20139. PMID: 23524901.","journal-title":"Infez Med"},{"key":"2815_CR61","doi-asserted-by":"publisher","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","volume":"1","author":"V Fabre","year":"2014","unstructured":"Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in combination with trimethoprim-sulfamethoxazole for Salvage therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and endocarditis. Open Forum Infect Dis. 2014;1:ofu046.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2815_CR62","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jjcc.2008.06.007","volume":"53","author":"T Fujino","year":"2009","unstructured":"Fujino T, Amari Y, Mohri M, et al. MRSA tricuspid valve infective endocarditis with multiple embolic lung abscesses treated by combination therapy of vancomycin, rifampicin, and sulfamethoxazole\/trimethoprim. J Cardiol. 2009;53(1):146\u20139.","journal-title":"J Cardiol"},{"issue":"4","key":"2815_CR63","doi-asserted-by":"publisher","first-page":"e01743","DOI":"10.1128\/AAC.01743-18","volume":"63","author":"R Kebriaei","year":"2019","unstructured":"Kebriaei R, Rice SA, Stamper KC, et al. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic\/pharmacokinetic model. Antimicrob Agents Chemother. 2019;63(4):e01743\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2815_CR64","doi-asserted-by":"publisher","first-page":"dlab099","DOI":"10.1093\/jacamr\/dlab099","volume":"3","author":"A Guleri","year":"2021","unstructured":"Guleri A, More R, Sharma R, et al. Use of dalbavancin in infective endocarditis: a case series. JAC Antimicrob Resist. 2021;3(3):dlab099.","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"2815_CR65","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jmii.2023.07.010","volume":"56","author":"SH Kim","year":"2023","unstructured":"Kim SH, Jeon M, Jang S, et al. Factors for mortality in patients with persistent Staphylococcus aureus bacteremia: the importance of treatment response rather than bacteremia duration. J Microbiol Immunol Infect. 2023;56(5):1007\u201315.","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"2815_CR66","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dkad005","volume":"78","author":"C Robson","year":"2023","unstructured":"Robson C, Tan B, Stuart R, et al. A systematic review of optimal pharmacokinetic\/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis. J Antimicrob Chemother. 2023;78(3):599\u2013612.","journal-title":"J Antimicrob Chemother"},{"key":"2815_CR67","first-page":"204993612412962","volume":"12","author":"S De Gregori","year":"2025","unstructured":"De Gregori S, De Silvestri A, Capone M, et al. A prospective study to evaluate high dose daptomycin pharmacokinetics and pharmacodynamics in Staphylococcus spp. infective endocarditis. Ther Adv Infect Dis. 2025;12:20499361241296232.","journal-title":"Ther Adv Infect Dis"},{"issue":"2","key":"2815_CR68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jiac.2019.10.003","volume":"26","author":"T Horino","year":"2020","unstructured":"Horino T, Hori S. Metastatic infection during Staphylococcus aureus bacteremia. J Infect Chemother. 2020;26(2):162\u20139.","journal-title":"J Infect Chemother"},{"issue":"2","key":"2815_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MD.0b013e31824d7ed2","volume":"91","author":"FJ Vos","year":"2012","unstructured":"Vos FJ, Kullberg BJ, Sturm PD, et al. Metastatic infectious disease and clinical outcome in Staphylococcus aureus and Streptococcus species bacteremia. Med (Baltim). 2012;91(2):86\u201394.","journal-title":"Med (Baltim)"},{"key":"2815_CR70","doi-asserted-by":"publisher","first-page":"106975","DOI":"10.1016\/j.ijid.2024.02.018","volume":"142","author":"J Donnelly","year":"2024","unstructured":"Donnelly J, McDermott H, Gash S, et al. Getting to the heart of the matter-are two agents really better than one for the treatment of staphylococcal infective endocarditis? Int J Infect Dis. 2024;142:106975.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"2815_CR71","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3390\/microorganisms12112226","volume":"12","author":"P Farahani","year":"2024","unstructured":"Farahani P, Ruffin F, Taherahmadi M, et al. Combination therapy is not associated with decreased mortality in infectious endocarditis: a systematic review and meta-analysis. Microorganisms. 2024;12(11):2226.","journal-title":"Microorganisms"},{"issue":"4","key":"2815_CR72","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1007\/s40121-021-00539-y","volume":"10","author":"C Ye","year":"2021","unstructured":"Ye C, Wang C, Li Z, et al. The effect of combination therapy on mortality and adverse events in patients with Staphylococcus aureus Bacteraemia: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Ther. 2021;10(4):2643\u201360.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2815_CR73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","volume":"3","author":"KE Barber","year":"2014","unstructured":"Barber KE, Ireland CE, Bukavyn N, et al. Observation of seesaw effect with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3(1):35\u201343.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"2815_CR74","doi-asserted-by":"publisher","first-page":"107469","DOI":"10.1016\/j.ijantimicag.2025.107469","volume":"65","author":"M Chen","year":"2025","unstructured":"Chen M, Jiang S, Sun L, et al. Seesaw effect between daptomycin and ceftobiprole in daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates. Int J Antimicrob Agents. 2025;65(5):107469.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2815_CR75","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40121-021-00412-y","volume":"10","author":"D Yahav","year":"2021","unstructured":"Yahav D, Shepshelovich D, Tau N. Cost analysis of new antibiotics to treat multidrug-resistant Bacterial infections: mind the gap. Infect Dis Ther. 2021;10(1):621\u201330.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"2815_CR76","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/diagnostics10100830","volume":"10","author":"AR Buonomini","year":"2020","unstructured":"Buonomini AR, Riva E, Di Bonaventura G, et al. Rapid detection of methicillin-resistant Staphylococcusaureus directly from blood for the diagnosis of bloodstream infections: a mini-review. Diagnostics (Basel). 2020;10(10):830.","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"2815_CR77","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","volume":"20","author":"R Kuehl","year":"2020","unstructured":"Kuehl R, Morata L, Boeing C, et al. International Staphylococcus aureus collaboration study group and the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis. 2020;20(12):1409\u201317.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2815_CR78","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/cid\/ciad784","volume":"78","author":"TW van der Vaart","year":"2024","unstructured":"van der Vaart TW, Prins JM, Goorhuis A, et al. The utility of risk factors to define complicated Staphylococcus aureus Bacteremia in a setting with low methicillin-resistant S. aureus prevalence. Clin Infect Dis. 2024;78(4):846\u201354.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2815_CR79","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11908-014-0429-6","volume":"16","author":"JR Smith","year":"2014","unstructured":"Smith JR, Claeys KC, Barber KE, et al. High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep. 2014;16(10):429.","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"2815_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijantimicag.2016.04.022","volume":"48","author":"E Durante-Mangoni","year":"2016","unstructured":"Durante-Mangoni E, Andini R, Parrella A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016;48(1):61\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2815_CR81","first-page":"446","volume":"29","author":"A Legg","year":"2023","unstructured":"Legg A, Davis JS, Roberts JA. Optimal drug therapy for Staphylococcus aureus bacteraemia in adults. Curr Opin Crit Care. 2023;29(5):446\u201356.","journal-title":"Curr Opin Crit Care"},{"issue":"12","key":"2815_CR82","doi-asserted-by":"publisher","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","volume":"20","author":"N Ghosh","year":"2014","unstructured":"Ghosh N, Chavada R, Maley M, et al. Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20(12):O1098\u2013105.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2815_CR83","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/AAC.05609-11","volume":"56","author":"J Brown","year":"2012","unstructured":"Brown J, Brown K, Forrest A. Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56(2):634\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2815_CR84","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.ijantimicag.2023.106749","volume":"61","author":"T Fazili","year":"2023","unstructured":"Fazili T, Bansal E, Garner D, et al. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review. Int J Antimicrob Agents. 2023;61(4):106749.","journal-title":"Int J Antimicrob Agents"},{"key":"2815_CR85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","volume":"138","author":"M Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez M, P\u00e9rez-Landeiro A, Sanjurjo A, et al. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis. Int J Infect Dis. 2024;138:41\u20135.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"2815_CR86","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamainternmed.2020.0555","volume":"180","author":"B Spellberg","year":"2020","unstructured":"Spellberg B, Chambers HF, Musher DM, et al. Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review. JAMA Intern Med. 2020;180(5):769\u201377.","journal-title":"JAMA Intern Med"},{"key":"2815_CR87","doi-asserted-by":"publisher","first-page":"117084","DOI":"10.1016\/j.bios.2024.117084","volume":"271","author":"Q Wang","year":"2025","unstructured":"Wang Q, Li X, Ren Y, et al. Rapid and precise treatment selection for antimicrobial-resistant infection enabled by a nano-dilution SlipChip. Biosens Bioelectron. 2025;271:117084.","journal-title":"Biosens Bioelectron"},{"key":"2815_CR88","doi-asserted-by":"publisher","first-page":"635831","DOI":"10.3389\/fmed.2021.635831","volume":"8","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Humphries R. Rapid antimicrobial susceptibility testing methods for blood cultures and their clinical impact. Front Med (Lausanne). 2021;8:635831.","journal-title":"Front Med (Lausanne)"},{"key":"2815_CR89","doi-asserted-by":"publisher","first-page":"1336821","DOI":"10.3389\/fcimb.2024.1336821","volume":"14","author":"K Liu","year":"2024","unstructured":"Liu K, Wang C, Zhou X, et al. Bacteriophage therapy for drug-resistant Staphylococcus aureus infections. Front Cell Infect Microbiol. 2024;14:1336821.","journal-title":"Front Cell Infect Microbiol"},{"key":"2815_CR90","doi-asserted-by":"publisher","first-page":"1356179","DOI":"10.3389\/fphar.2024.1356179","volume":"15","author":"A Loganathan","year":"2024","unstructured":"Loganathan A, Bozdogan B, Manohar P, et al. Phage-antibiotic combinations in various treatment modalities to manage MRSA infections. Front Pharmacol. 2024;15:1356179.","journal-title":"Front Pharmacol"},{"issue":"12","key":"2815_CR91","doi-asserted-by":"publisher","first-page":"12026","DOI":"10.1021\/acsomega.4c09831","volume":"10","author":"MD Tadesse","year":"2025","unstructured":"Tadesse MD, Ali N, White M, et al. One-Two Punch: Phage-Antibiotic Synergy Observed against Staphylococcus aureus by Combining Pleurotin and Phage K. ACS Omega. 2025;10(12):12026\u201336.","journal-title":"ACS Omega"},{"issue":"3","key":"2815_CR92","doi-asserted-by":"publisher","first-page":"e023080","DOI":"10.1161\/JAHA.121.023080","volume":"11","author":"J Save","year":"2022","unstructured":"Save J, Que YA, Entenza JM, et al. Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis. J Am Heart Assoc. 2022;11(3):e023080.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2815_CR93","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/v14081792","volume":"14","author":"J Save","year":"2022","unstructured":"Save J, Que YA, Entenza J, et al. Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Viruses. 2022;14(8):1792.","journal-title":"Viruses"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02815-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:02:04Z","timestamp":1786705324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02815-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02815-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}